Table 1.
Characteristics of study subjects (N = 137)
| Characteristic | Cases (%) |
|---|---|
| Age (years) | |
| ≤50 | 78 (56.93) |
| >50 | 59 (43.07) |
| Age at menarche | |
| ≤12 | 26 (18.98) |
| >12 | 111 (81.02) |
| Menopausal status | |
| Premenopausal | 40 (29.20) |
| Postmenopausal | 97 (70.80) |
| Age at menopause | |
| ≤45 | 33 (34.02) |
| >45 | 64 (65.98) |
| ER status | |
| Positive | 81 (59.12) |
| Negative | 56 (40.88) |
| PR status | |
| Positive | 47 (34.31) |
| Negative | 90 (65.69) |
| Her2 status | |
| Positive | 66 (48.18) |
| Negative | 71 (51.82) |
| Molecular subtypes of breast cancer | |
| Luminal A | 46 (33.58) |
| Luminal B | 38 (27.74) |
| Her2-enriched | 28 (20.44) |
| TNBC | 25 (18.25) |
| Tumor size | |
| ≤5 | 55 (40.15) |
| >5 | 82 (59.85) |
| Lymph node status | |
| Positive | 99 (72.26) |
| Negative | 38 (27.74) |
| Clinical stage | |
| I+II | 45(32.85) |
| III+IV | 92(67.15) |
| Histological grade | |
| I+II | 95 (69.34) |
| III | 42 (30.66) |